Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Parallel Controlled, Multicenter Phase II Clinical Study of Carelizumab Combined With TCb (Docetaxel+Carboplatin) Versus TCb Neoadjuvant Therapy for Triple Negative Breast Cancer

NCT05475678 is registered in ClinicalTrials.gov with Zhenzhen Liu as lead sponsor.

NCT NCT05475678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05475678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Parallel Controlled, Multicenter Phase II Clinical Study of Carelizumab Combined With TCb (Docetaxel+Carboplatin) Versus TCb Neoadjuvant Therapy for Triple Negative Breast Cancer
Lead sponsor
Zhenzhen Liu
Phase
Phase 2
Overall status
Recruiting
Start date
December 20, 2022
Completion date
December 31, 2029
Enrollment
369 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, camrelizumab, triple negative breast cancer